2156649-32-8
Chemical Structure
Elunetirom
Synonym(s): MA-JD21; ABX-002
- CAS No.: 2156649-32-8
- Formula:C19H21Cl2NO3
- Molecular Weight:382.28
InChIKey: CQELSEDWYWTMDG-UHFFFAOYSA-N
SMILES: O=C(COC1=CC(Cl)=C(CC2=CC=C(C(C(C)C)=C2)O)C(Cl)=C1)NC
Biological Activity: Elunetirom (MA-JD21) is an orally active, blood-brain barrier-permeable prodrug of LL-340001. Elunetirom employs fatty acid amide hydrolase (FAAH)-dependent prodrug technology to enhance the brain delivery of LL-340001, a potent thyroid hormone receptor agonist with 15-fold higher selectivity for TRβ over TRα. Elunetirom induces T3-regulated gene expression, including that of ABCD2. Elunetirom drives neuroplasticity and bioenergetic changes, and induces neurogenesis, neuritogenesis, and synaptogenesis. Elunetirom is applicable to research related to major depressive disorder and X-linked adrenoleukodystrophy[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Elunetirom | 99.24% | Elunetirom (MA-JD21) is an orally active, blood-brain barrier-permeable prodrug of LL-340001. Elunetirom employs fatty acid amide hydrolase (FAAH)-dependent prodrug technology to enhance the brain delivery of LL-340001, a potent thyroid hormone receptor agonist with 15-fold higher selectivity for TRβ over TRα. Elunetirom induces T3-regulated gene expression, including that of ABCD2. Elunetirom drives neuroplasticity and bioenergetic changes, and induces neurogenesis, neuritogenesis, and synaptogenesis. Elunetirom is applicable to research related to major depressive disorder and X-linked adrenoleukodystrophy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Harris J R, et al. Elunetirom (ABX-002), a first-in-class, brain-targeting, antidepressant candidate in Ph2 development, triggers robust bioenergetic and neuroplastic improvements in preclinical studies[J].
- [2]. MacKenna D, et al. ABX-002: A fatty-acid amide hydrolase (FAAH) activated prodrug enhances functional delivery of a potent TR-β selective thyromimetic to the brain and demonstrates biological activity in models of X-linked Adrenoleukodystrophy (2442)[J]. Neurology, 2021, 96(15_supplement): 2442.
